-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
To this end, the researchers screened 20 potential treatments in mouse models that have the same genetic defects as humans with retinitis pigmentosa. Experiments have shown that in three different mouse models, using a viral vector to deliver a gene called Txnip is the most effective way to treat this disease. The research team later proved that gene therapy to reduce oxidative stress and inflammation in mice, coupled with Txnip gene therapy, can provide additional protection for eye cells. "The next step is to test the safety of Txnip on animals other than mice, and then conduct human clinical trials. Related paper information: org/10. org/10. |